Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Change in Receivables (2019 - 2025)

Cue Biopharma's Change in Receivables history spans 7 years, with the latest figure at -$145000.0 for Q3 2025.

  • For Q3 2025, Change in Receivables fell 111.11% year-over-year to -$145000.0; the TTM value through Sep 2025 reached -$2.8 million, down 285.32%, while the annual FY2024 figure was -$753000.0, 145.89% down from the prior year.
  • Change in Receivables for Q3 2025 was -$145000.0 at Cue Biopharma, down from $532000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $2.4 million in Q4 2021 and bottomed at -$2.2 million in Q1 2022.
  • The 5-year median for Change in Receivables is $38000.0 (2023), against an average of -$54208.2.
  • The largest annual shift saw Change in Receivables tumbled 55350.0% in 2022 before it skyrocketed 776.67% in 2023.
  • A 5-year view of Change in Receivables shows it stood at $2.4 million in 2021, then tumbled by 131.13% to -$738000.0 in 2022, then soared by 105.15% to $38000.0 in 2023, then crashed by 5907.89% to -$2.2 million in 2024, then soared by 93.43% to -$145000.0 in 2025.
  • Per Business Quant, the three most recent readings for CUE's Change in Receivables are -$145000.0 (Q3 2025), $532000.0 (Q2 2025), and -$945000.0 (Q1 2025).